STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1249 by analyst upside · 2026-06-27
ORKA
Oruka Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+56.9%
implied upside to consensus target
Current Price $90.6
Consensus Target $142.17
Bull Target $200.0
Bear Target $100.0
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
10
Hold
0
Sell
0
52-Week Low $10.83
52-Week High $91.12
YTD Return +220.5%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -36.8x
EPS (TTM) $-2.02
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $10.83
52-Week High $91.12
Current Price $90.6
Bear Target $100.0
Bull Target $200.0
● Now $90.6 ● Target $142.17
TRADING DATA
Avg Volume 1.7M
YTD Return +220.5%
Analyst Count 12
Consensus Buy
Upside to Target +56.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Oruka Therapeutics, Inc. (ORKA) is currently trading at $90.6 with a Wall Street consensus price target of $142.17, implying potential upside of 56.9% over the next 12 months. 12 analysts currently cover ORKA, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $200.0, while the most cautious has a target of $100.0.

ORKA operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 220.5% year-to-date and is currently trading near the upper end of its 52-week range of $10.83 – $91.12.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ORKA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-18 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-05-14 38% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-29 31% win rate (48 calls)
UBS — Reiterated
Buy → Buy 2026-04-28 33% win rate (6 calls)
Barclays — Reiterated
Overweight → Overweight 2026-04-28 Building track record
BTIG — Reiterated
Buy → Buy 2026-04-27 38% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-04-15 Building track record
Guggenheim reit
Buy → Buy 2026-04-13 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →